Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 9.8% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics Inc (NASDAQ:NTLA) is a biotechnology company specializing in CRISPR/Cas9 gene editing technology for therapeutic purposes. Market sentiment for biotech stocks has been volatile recently due to regulatory developments and clinical trial outcomes.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 9.8% on Oct 30, 2025 14:06

• Intellia Therapeutics (NTLA) stock saw a significant drop in after-hours trading subsequent to the FDA's decision to place a clinical hold on some of its Investigational New Drug applications.
• The regulatory setback from the FDA has likely caused concerns among investors regarding potential delays in the company's drug development pipeline and its financial implications.
• This news prompted a sell-off as investors reassessed Intellia Therapeutics' short-term outlook, leading to a notable decrease in NTLA stock price.
• The bearish trend in NTLA stock may continue until there is more clarity on the FDA's issues and the company's plan to address them, underscoring the significance of regulatory risks in the biotech sector.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics Stock Is Diving Again: Here's Why - Intellia Therapeutics ( NASDAQ:NTLA )

Intellia Therapeutics Inc ( NASDAQ:NTLA ) shares are tumbling in after-hours trading on Wednesday after the company announced the U.S. Food and Drug Administration ( FDA ) placed a clinical hold on some of its Investigational New Drug ( IND ) applications.

https://www.benzinga.com/trading-ideas/movers/25/10/48514659/intellia-therapeutics-stock-is-diving-again-heres-why

This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Cadence Bank ( NYSE:CADE ) , Boot Barn Holdings ( NYSE:BOOT )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Seaport Global analyst Mitch Kummetz downgraded the rating for Boot Barn Holdings Inc ( ...

https://www.benzinga.com/news/25/10/48457193/this-boot-barn-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-tuesday

Trending Today

Solana ($SOL) Crypto Forecast: Down 5.3% Today

Gasoline ($GASOLINE) Commodity Forecast: Down 4.9% Today

Dogecoin ($DOGE) Crypto Forecast: Down 8.5% Today

XRP ($XRP) Crypto Forecast: Down 7.3% Today

S&P 500 Index ($SPX) Index Forecast: Down 0.4% Today

NASDAQ-100 ($NDX) Index Forecast: Down 0.3% Today

Binance Coin ($BNB) Crypto Forecast: Down 5.3% Today

International Paper Company ($IP) Stock Forecast: Down 12.4% Today

The Boeing Company ($BA) Stock Forecast: Down 6.2% Today

Roblox Corp ($RBLX) Stock Forecast: Down 16.0% Today

Intellia Therapeutics, Inc. Price History

18.08.2025 - NTLA Stock was up 25.5%

• The surge in Intellia Therapeutics' stock price followed the completion of Phase 3 enrollment for its HAELO trial ahead of schedule, demonstrating progress in its pipeline development.
• Investor optimism and confidence were likely enhanced by the anticipation of Phase 3 topline data, expected in the first half of 2026.
• The bullish movement in Intellia's stock was influenced by positive market sentiment, with major indices like the Nasdaq Composite gaining over 200 points, reflecting increased interest in growth stocks in the biotech sector.

22.08.2025 - NTLA Stock was up 5.8%

• The stock of NTLA showed a strong bullish movement today.
• The completion of enrollment in the pivotal phase III HAELO study on lonvo-z for hereditary angioedema led to a nearly 30% surge in Intellia shares.
• Positive longer-term data from the ongoing Phase 1 clinical trial of Nexiguran Ziclumeran for the treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy also increased investor confidence.
• The expectation of Phase 3 topline data in the first half of 2026 further added to the positive sentiment surrounding Intellia Therapeutics.

22.09.2025 - NTLA Stock was down 6.5%

• The bearish movement in NTLA's stock today could be due to concerns about the competition in the gene editing space.
• Investors may be cautious about the company's ability to maintain a competitive edge in the market, especially with the focus on its in vivo pipeline for long-term growth.
• The market might be reacting to uncertainties surrounding the success and commercialization of Intellia's late-stage gene-editing therapies, lonvo-z and nex-z.
• Overall, the negative market sentiment towards NTLA today could be influenced by doubts about the company's future growth prospects amidst a competitive landscape in the gene editing industry.

28.09.2025 - NTLA Stock was down 6.8%

• The downward movement in NTLA stock could be tied to the overall negative sentiment in the biotechnology sector, possibly influenced by the recent downgrade of Boot Barn Holdings Inc. by a prominent Wall Street analyst.
• This shift in analyst perspective may have impacted investor trust in the sector, resulting in a sell-off of NTLA shares.
• Investors appear to be exercising caution regarding the future potential of gene editing technologies, including CRISPR/Cas9, in light of recent analyst actions and broader market patterns.

08.09.2025 - NTLA Stock was up 25.1%

• Analysts on Wall Street foresee a 63.7% upside potential for NTLA, reflecting favorable sentiment towards the stock.
• The company disclosed inducement grants in line with Nasdaq Listing Rule 5635, highlighting efforts to attract top talent and foster innovation.
• The rising trend in earnings estimate revisions may have contributed to the stock's bullish performance.
• Overall, positive developments and optimistic analyst projections appear to have propelled the strong bullish trend in Intellia Therapeutics' stock today.

30.09.2025 - NTLA Stock was down 9.8%

• Intellia Therapeutics (NTLA) stock saw a significant drop in after-hours trading subsequent to the FDA's decision to place a clinical hold on some of its Investigational New Drug applications.
• The regulatory setback from the FDA has likely caused concerns among investors regarding potential delays in the company's drug development pipeline and its financial implications.
• This news prompted a sell-off as investors reassessed Intellia Therapeutics' short-term outlook, leading to a notable decrease in NTLA stock price.
• The bearish trend in NTLA stock may continue until there is more clarity on the FDA's issues and the company's plan to address them, underscoring the significance of regulatory risks in the biotech sector.

09.09.2025 - NTLA Stock was up 5.1%

• NTLA experienced a significant increase of 19.7% in its shares, accompanied by above-average trading volume.
• Analysts from Wall Street are optimistic about NTLA, projecting a potential upside of 63.7% for the stock, reflecting favorable market sentiment.
• Recent changes in earnings estimates for Intellia Therapeutics may have contributed to the price surge, hinting at further growth in the short term.
• The company disclosed the provision of inducement grants under Nasdaq Listing Rule 5635 (c)(4), potentially enhancing investor confidence in the company's future prospects.

25.08.2025 - NTLA Stock was down 5.3%

• Despite positive progress on key clinical studies, the market response may have been dampened by the absence of immediate revenue-generating activities or commercialization opportunities.
• Investors could be capitalizing on recent stock price gains following a successful enrollment completion in a pivotal study for lonvo-z in hereditary angioedema.
• Concerns surrounding the timeline for Phase 3 data release in 2026 might have contributed to a shift in market sentiment, prompting a sell-off of the stock.
• The general downward trend could also be a result of broader market conditions or sector rotations affecting biotech stocks, leading traders to reassess their positions in NTLA.

07.09.2025 - NTLA Stock was down 5.4%

• The drop in NTLA stock could be a result of investors taking profits following a recent increase in the stock's value.
• Concerns among investors about the potential dilution of current shares due to the announcement of inducement grants may have triggered a sell-off.
• Investors could be reexamining their positions in NTLA stock due to apprehensions about competition within the gene editing industry.

19.08.2025 - NTLA Stock was up 11.0%

• Intellia Therapeutics (NTLA) witnessed a substantial 29.8% surge in its stock price.
• The Phase 3 HAELO trial enrollment completion ahead of schedule and the expected release of Phase 3 topline data in the first half of 2026 were factors contributing to the positive momentum.
• The optimistic trend in earnings estimate revisions also bolstered the stock's upward trajectory.
• In conclusion, Intellia Therapeutics' impressive performance was fueled by advancements in its clinical trials and positive market outlook towards the biotechnology industry.

16.08.2025 - NTLA Stock was up 5.8%

• Factors contributing to the upward trend in NTLA include:
• Favorable market feelings towards biotech firms
• Possible breakthroughs or progress in CRISPR technology
• Speculation or expectation of future positive events or advancements within the company

18.08.2025 - NTLA Stock was up 14.7%

• Intellia Therapeutics Inc. (NTLA) experienced a strong bullish movement today.
• The overall bullish sentiment in the market, with the Nasdaq Composite gaining over 200 points, likely contributed to the positive movement in NTLA.
• The acquisition announcement by Radian Group Inc. (RDN) for $1.7 billion may have also boosted investor confidence in the biotechnology sector, including companies like Intellia Therapeutics Inc.
• The positive market momentum and the acquisition news could have created a favorable environment for NTLA, leading to its strong bullish movement today.